Please note that due to a high volume of submissions, the ANZCTR is currently experiencing a delay in processing of submissions.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00196989




Registration number
NCT00196989
Ethics application status
Date submitted
13/09/2005
Date registered
20/09/2005
Date last updated
23/03/2017

Titles & IDs
Public title
Study In People With Type 2 Diabetes
Scientific title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Secondary ID [1] 0 0
ADG20001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Diabetes Mellitus, Type 2 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Pioglitazone
Treatment: Drugs - GW677954

Treatment: Drugs: Pioglitazone


Treatment: Drugs: GW677954


Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage change from Baseline (Day 1) in glycated hemoglobin (HbA1c) levels at Week 16 as a measure of improvement in glucose control - Improvement in glucose control was measured by means of reduction in glycated hemoglobin (Hb) levels in blood.
Timepoint [1] 0 0
Week (W) 16
Secondary outcome [1] 0 0
Percentage change from Baseline (Day 1) in fasting HbA1c levels at Weeks 4, 8 and 12 - Improvement in glucose control was measured by means of reduction in glycated hemoglobin (HbA1c) levels in blood. Change from Baseline is the value at indicated time point minus the value at Baseline.
Timepoint [1] 0 0
Weeks 4, 8, and 12
Secondary outcome [2] 0 0
Change from Baseline (Day 1) in fasting plasma glucose (FPG) at Weeks 1, 2, 4, 6, 8, 12 and 16 - Change from Baseline is the value at indicated time point minus the value at Baseline.
Timepoint [2] 0 0
W1, W2, W4, W6, W8, W12, and W16
Secondary outcome [3] 0 0
Change from Baseline (Day 1) in fasting fructosamine at Weeks 2 and 4 - Change from Baseline is the value at indicated time point minus the value at Baseline.
Timepoint [3] 0 0
Baseline (Day 1), W2, W4
Secondary outcome [4] 0 0
Percentage of participants achieving target HbA1c levels at Weeks 4, 8, 12, and 16 - Improvement in glucose control was measured by means of reduction in glycated hemoglobin (HbA1c) levels in blood. The ideal concentration of HbA1c was desired to be less than or equal to 7%.
Timepoint [4] 0 0
Weeks 4, 8, 12, and 16
Secondary outcome [5] 0 0
Percentage of participants achieving a decrease in HbA1c of >= 0.7% from Baseline (Day 1) at Weeks 4, 8, 12 and 16 - Improvement in glucose control was measured by means of reduction in glycated hemoglobin (HbA1c) levels in blood.
Timepoint [5] 0 0
Baseline (Day 1), Weeks 4, 8, 12, and 16
Secondary outcome [6] 0 0
Percentage of participants achieving target range of FPG at Weeks 1, 2, 4, 6, 8, 12 and 16 - The target range for FPG was <=126 milligrams per deciliter (mg/dL) or 7.0 millimoles per liter (mmol/L) to <=140 mg/dL or 7.8 mmol/L
Timepoint [6] 0 0
Weeks 1,2, 4, 6, 8, 12, and 16
Secondary outcome [7] 0 0
Percentage of participants achieving a decrease from Baseline (Day 1) of >=30 mg/dL [1.66 mmol/L] in FPG at Weeks 1, 2, 4, 6, 8, 12 and 16 - Change from Baseline is the value at indicated time point minus the value at Baseline.
Timepoint [7] 0 0
Weeks 1, 2, 4, 6, 8, 12, and 16
Secondary outcome [8] 0 0
Ratio to the Baseline (percentage change) of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and free fatty acids (FFA) at Weeks 2, 4, 8, 12, and 16 - This data analysis was based on log-transformed data.
Timepoint [8] 0 0
Baseline (Day 1), Weeks 2, 4, 8, 12, and 16
Secondary outcome [9] 0 0
Percentage change from Baseline (Day 1) in non-HDL-C based on log-transformed data at Week 16 - Change from Baseline is the value at indicated time point minus the value at Baseline.
Timepoint [9] 0 0
At Week 16
Secondary outcome [10] 0 0
Percentage change from Baseline (Day 1) in very low density lipoprotein-cholesterol (VLDL-C), apolipoprotein AI (Apo AI), AII, and B at Week 16. - Change from Baseline is the value at indicated time point minus the value at Baseline.
Timepoint [10] 0 0
At Week 16
Secondary outcome [11] 0 0
Change from Baseline (Day 1) in Apo B/TC, TC/HDL-C, and LDL-C/Apo B ratio at Week 16 - Change from Baseline is the value at indicated time point minus the value at Baseline.
Timepoint [11] 0 0
At Week 16
Secondary outcome [12] 0 0
Change from Baseline (Day 1) in hemoglobin at Week 16 - This analysis was performed in sitting position. Change from Baseline is the value at indicated time point minus the value at Baseline.
Timepoint [12] 0 0
At Week 16
Secondary outcome [13] 0 0
Change from Baseline (Day 1) in hematocrit at Week 16 - Change from Baseline is the value at indicated time point minus the value at Baseline.
Timepoint [13] 0 0
Wekk 16
Secondary outcome [14] 0 0
Change from Baseline (Day 1) in systolic and diastolic blood pressure (SBP and DBP) at Week 16 - Systolic blood pressure )SBP) and diastolic blood pressure (DBP) were measured in sitting position. Change from Baseline is the value at indicated time point minus the value at Baseline.
Timepoint [14] 0 0
At Week 16
Secondary outcome [15] 0 0
Change from Baseline (Day 1) in heart rate at Week 16 - Heart rate was measured in sitting position. Change from Baseline is the value at indicated time point minus the value at Baseline.
Timepoint [15] 0 0
Week 16
Secondary outcome [16] 0 0
Change from Baseline (Day 1) in body weight at Week 16 - Change from Baseline is the value at indicated time point minus the value at Baseline.
Timepoint [16] 0 0
Week 16
Secondary outcome [17] 0 0
Change from Baseline (Day 1) in 12 lead electrocardiogram (ECG) measures including PR interval, QT interval, QTc interval and QRS duration at Week 16 - QT(c) interval calculations were done by Bazett's method (QTc[B]) as well as by Fridericia's correction (QTc[F]). Change from Baseline is the value at indicated time point minus the Baseline value.
Timepoint [17] 0 0
Week 16
Secondary outcome [18] 0 0
Number of participants with clinical hematology, chemistry, urinalysis, exploratory cardiac parameters of potential clinical concern (PCC) along with serum pregnancy test over period - Participants were analyzed for any abnormality for laboratory parameters either higher or lower than the potential clinical concern range.
Timepoint [18] 0 0
Upto 16 weeks
Secondary outcome [19] 0 0
Number of participants with hypoglycemic events as a measure of ophthalmic assessment - Participants received a glucose log for reading for routine recording of glucometer readings. Glucose values were recorded on timely basis.
Timepoint [19] 0 0
Up to 16 weeks
Secondary outcome [20] 0 0
Number of participants with intensity of hypoglycemic events as a measure of ophthalmic assessment - Participants received a glucose log for reading for routine recording of glucometer readings. Glucose values were recorded on timely basis.
Timepoint [20] 0 0
Up to 16 weeks
Secondary outcome [21] 0 0
Number of participants with adverse events (AEs) and serious adverse events (SAEs) over period - Adverse event (AE) is an unfavorable change in the health of a participant, including abnormal laboratory findings, that happens during a clinical study or within a certain time period after the study has ended. This change may or may not be caused by the intervention being studied. Serious adverse event (SAE) is an adverse event that results in death, is life-threatening, requires inpatient hospitalization or extends a current hospital stay, results in an ongoing or significant incapacity or interferes substantially with normal life functions, or causes a congenital anomaly or birth defect. Medical events that do not result in death, are not life-threatening, or do not require hospitalization may be considered serious adverse events if they put the participant in danger or require medical or surgical intervention to prevent one of the results listed above.
Timepoint [21] 0 0
Up to 16 weeks
Secondary outcome [22] 0 0
Change from Baseline (Day 1) in phosphocreatine kinase (Creatine kinase-MB) over period - CK-MB is a cardiac biomarker.
Timepoint [22] 0 0
Up to 16 weeks
Secondary outcome [23] 0 0
Number of participants with absolute Troponin-I (cTnI) levels over period - Troponin-I (cTnI) is a cardiac biomarker.
Timepoint [23] 0 0
Up to 16 weeks
Secondary outcome [24] 0 0
Change from Baseline (Day 1) in fasting insulin at Week 8 and 16 - Change from Baseline is the value at indicated time point minus the value at Baseline.
Timepoint [24] 0 0
Week 8 and 16
Secondary outcome [25] 0 0
Change from Baseline (Day 1) in C-peptide at Week 8 and 16
Timepoint [25] 0 0
Week 8 and 16
Secondary outcome [26] 0 0
Change from Baseline (Day 1) in HOMA-S at Week 16
Timepoint [26] 0 0
Week 16
Secondary outcome [27] 0 0
Change from Baseline (Day 1) in QUICKI at Week 16
Timepoint [27] 0 0
Week 16

Eligibility
Key inclusion criteria
Inclusion criteria:

- Subjects with T2DM as defined by the criteria of the ADA and/or recognized by WHO
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus [American
Diabetes Association, 2004], for at least 3 months preceding screening (see Section
15.3, Appendix 3:, "Diagnosis and Classification of Diabetes Mellitus").

- To be eligible for Randomization into the trial, a subject must satisfy all of the
following glycemic criteria:

- HbA1c level via central laboratory at the pre-screening visit

- If HbA1c = 8.0% but = 10.0%: subject may proceed to Randomization;

- If HbA1c = 7.8% but < 8.0%, subject not eligible to proceed, but may be retested
once to establish eligibility (or lack thereof). If HbA1c level = 8.0% upon
retest, subject is eligible to proceed; otherwise they should be withdrawn.

- If HbA1c < 7.8%, subject not eligible to proceed (no retest allowed).

- FPG level via central laboratory at the pre-screening visit must be < 270 mg/dL
(15.0 mmol/L). FPG may be retested within a week to confirm eligibility (or lack
thereof).

- Concurrent T2DM therapy:

- Diet and/or exercise treated: Must not have taken antidiabetic medication for at
least 2 months prior to the pre-screening visit, OR

- Metformin monotherapy: Subjects entering the study on metformin must be on the
same dose, formulation and regimen of metformin for at least 2 months prior to
the pre-screening visit, AND

- TZDs and insulin are excluded in the 3 months prior to the Screening visit for
all subjects.

- Males and females who are 18 to 70 years of age inclusive at the time of Screening.

- If female, eligible to enter and participate in this study:

- If of non-childbearing potential (i.e., physiologically incapable of becoming
pregnant (tubal ligation), including any female who is post-menopausal [>1 year
without menstrual period]); or,

- If of child-bearing potential, has a negative pregnancy test at Screening
(serum), at Randomization (urine) and:

- Has a male partner who is sterile prior to the female subject's entry into
the study and is the sole sexual partner for that female subject, or

- Uses double-barrier methods of contraception; condoms with the use of caps
(with spermicide) and IUDs are acceptable, or

- Uses hormonal contraceptives (oral, depots, patches etc) with double-
barrier methods of contraception as outlined above, or

- Abstains from sexual intercourse, or

- Is with a same sex partner and does not participate in bisexual activities
where there is any risk of pregnancy.

- Body Mass Index (BMI): =25 and =40 kg/m² and weigh at least 50 kg at Screening.

- If subject is a smoker, must be able to abstain while in clinic at each visit.

- Subject has given full written informed consent prior to any study related procedures
are performed.
Minimum age
18 Years
Maximum age
70 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:



- Metabolic Disease including:

- Diagnosis of Type 1 diabetes mellitus

- Uncorrected thyroid dysfunction. (NOTE: subjects with hypothyroidism on a stable
dose of thyroid replacement therapy for at least 1 month prior to Screening, and
who have a screening thyroid stimulating hormone (TSH) within the upper limit of
normal may participate).

- Significant weight gain or loss (defined as > 5% of total body weight) within the
3 months prior to Screening.

- Previous use of insulin for treatment of hyperglycemia within 3 months of Screening.

- History of recent clinically significant cardiovascular disease including:

- History or ECG evidence of prior myocardial infarction within 6 months prior to
Screening.

- Current unstable angina or history of unstable angina in past 6 months.

- Coronary revascularization including percutaneous transluminal coronary
angioplasty (PTCA) or coronary artery bypass graft (CABG) surgery that is either
planned or occurred in the 6 months prior to Screening.

- Clinically significant arrhythmia or valvular heart disease.

- Congestive heart failure (CHF) with New York Heart Association (NYHA) Class II-IV
symptoms (see Section 15.4, Appendix 4).

- Blood pressure > 160/100 mmHg or resting heart rate > 100 bpm. Note: subjects
using antihypertensives [e.g., beta blockers, angiotensin converting enzyme (ACE)
inhibitors, angiotensin II antagonists, calcium channel blockers and diuretics]
must be on stable doses during the 30 days prior to Screening and during the
trial.

- Has a QTc interval (Bazett's) > 440 msec in males and > 450 msec in females at
Screening.

- Clinically significant ECG abnormalities which, in the opinion of the
Investigator, may affect the interpretation of safety data, or which otherwise,
contraindicates participation in a clinical trial with a new chemical entity.

- History of chronic pancreatitis.

- Familial hypercholesterolemia.

- TGs =800 mg/dL (8.96 mmol/L) at Screening.

- Serum creatinine at screening > 1.4 mg/dL (124 µmol/L) for women, or > 1.5 mg/dL (133
µmol/L) for men.

- Clinically significant anemia defined by hemoglobin concentrations <12.0 g/dL or <
120.0 g/L for males and < 11.0 g/dL or < 110.0 g/L for females.

- History of significant co-morbid diseases (e.g., cholelithiasis, gastrointestinal
disease, etc.) that would preclude participation in the study.

- Documented history of hepato-biliary disease including a history of, or positive
laboratory results for hepatitis (hepatitis B surface antigen and/or hepatitis C
antibody) at Screening, and/or clinically significant hepatic enzyme elevation
including:

•Any one of the following enzymes greater than 2.5 times the upper limit of normal
(ULN) value at Screening:

- Alanine aminotransferase (ALT)

- Aspartate aminotransferase (AST)

- Alkaline phosphatase (ALP)

- Total or direct bilirubin > 1.5 times the ULN at Screening, unless consistent
with presumed or diagnosed Gilbert's disease.

- History of metabolic acidosis, rhabdomyolysis, myalgia, myositis or myopathy after
taking statins or fibrates.

- Any subject who has withdrawn therapy due to AEs after taking a PPAR? or a PPARa/?
dual agonist, either marketed (e.g., troglitazone, rosiglitazone or pioglitazone) or
under current or previous clinical investigation.

- Signs or symptoms of myositis at Screening (or upon 1 repeat test), and/or creatinine
phosphokinase (CPK)=3.0 times ULN

- Is currently taking or has taken any of the following medications in the 3 months
prior to the pre-screening visit:

- Anti-obesity agents (including fat absorption blocking agents)

- St. John's Wort

- Warfarin and other oral anticoagulants (excluding aspirin and non-steroidal
anti-inflammatory drugs)

- Digoxin

- Oral or injectable corticosteroids (inhaled and intranasal steroids are
acceptable)

- Use of antidiabetic agents (other than metformin) in the 2 months prior to the
pre-screening visit.

- Use of TZDs in the 3 months prior to the pre-screening visit.

- Methotrexate, cyclosporine or monoclonal antibodies (e.g., alemtuzumab,
gemtuzumab ozogamicin, rituximab, trastuzumab, ibritumomab, tiuxetan) for
rheumatoid arthritis or psoriasis.

- Atypical antipsychotic medications [e.g., aripiprazole (Abilify), risperidone
(Risperdal), clozapine (Clozaril), olanzapine (Zyprexa), quetiapine (Seroquel),
and ziprasidone (Geodon)].

- Antiretroviral drugs

- Use of lipid lowering agents within 3 months prior to the pre-screening visit.
This includes statins, fibrates, ezetimibe (Zetia), niacin and bile acid
sequestrants.

- Monoamine oxidase inhibitors

- History of cancer except for the following:

- Basal cell carcinoma or superficial squamous cell carcinoma treated by local
excision.

- Cervical cancer in situ treated definitively more than 6 months prior to
screening.

- Women who are lactating, pregnant, or planning to become pregnant.

- Known immediate or delayed hypersensitivity reaction or idiosyncrasy to any drug
chemically related to the study drug.

- Known allergy to any of the capsule excipients, or history of drug or other allergy,
which, in the opinion of the responsible study physician, contradicts participation.
Hypersensitivity to metformin or any of its components (for subjects entering on
metformin).

- Has a history of substance and/or alcohol abuse within the past year as determined by
the Investigator at screening or during treatment:

- Unwilling to refrain from the use of illicit drugs and adhere to other
protocol-stated restrictions while participating in the study.

- History of alcohol abuse defined as an average weekly intake of greater than 21
units or an average daily intake of greater than 3 units (males) or defined as an
average weekly intake of greater than 14 units or an average daily intake of
greater than 2 units (females). One unit is equivalent to a half-pint of beer or
1 measure of spirits or 1 glass of wine.

- Received treatment with a new molecular entity (investigational drug) during the
previous 4 months or participated in any other trial during the previous 3 months, or
has participated in a previous study with GW677954. A new molecular entity is defined
as any compound not in Phase 3. (The washout is from last dose of investigational
product in the previous study until the first dose of investigational product.)

- Likely to be non-compliant, in the investigator's opinion, with respect to the
protocol and related scheduled visits.

- Subject has any concomitant medical condition which in the opinion of the investigator
makes them unsuitable to participate in the study.

- Subject is either an immediate family member of a participating investigator, study
coordinator, employee of an investigator; or is a member of the staff conducting the
study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Recruitment hospital [1] 0 0
GSK Investigational Site - Miranda
Recruitment hospital [2] 0 0
GSK Investigational Site - Carina Heights
Recruitment hospital [3] 0 0
GSK Investigational Site - Spring Hill
Recruitment hospital [4] 0 0
GSK Investigational Site - Adelaide
Recruitment hospital [5] 0 0
GSK Investigational Site - Keswick
Recruitment hospital [6] 0 0
GSK Investigational Site - Port Lincoln
Recruitment hospital [7] 0 0
GSK Investigational Site - Box Hill
Recruitment hospital [8] 0 0
GSK Investigational Site - Ringwood East
Recruitment postcode(s) [1] 0 0
2228 - Miranda
Recruitment postcode(s) [2] 0 0
4152 - Carina Heights
Recruitment postcode(s) [3] 0 0
4000 - Spring Hill
Recruitment postcode(s) [4] 0 0
5000 - Adelaide
Recruitment postcode(s) [5] 0 0
5035 - Keswick
Recruitment postcode(s) [6] 0 0
5606 - Port Lincoln
Recruitment postcode(s) [7] 0 0
3128 - Box Hill
Recruitment postcode(s) [8] 0 0
3135 - Ringwood East
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Hawaii
Country [9] 0 0
United States of America
State/province [9] 0 0
Illinois
Country [10] 0 0
United States of America
State/province [10] 0 0
Indiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Missouri
Country [13] 0 0
United States of America
State/province [13] 0 0
Nevada
Country [14] 0 0
United States of America
State/province [14] 0 0
New Mexico
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
North Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Pennsylvania
Country [19] 0 0
United States of America
State/province [19] 0 0
Rhode Island
Country [20] 0 0
United States of America
State/province [20] 0 0
South Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
Tennessee
Country [22] 0 0
United States of America
State/province [22] 0 0
Texas
Country [23] 0 0
United States of America
State/province [23] 0 0
Utah
Country [24] 0 0
United States of America
State/province [24] 0 0
Virginia
Country [25] 0 0
United States of America
State/province [25] 0 0
Washington
Country [26] 0 0
United States of America
State/province [26] 0 0
Wisconsin
Country [27] 0 0
Argentina
State/province [27] 0 0
Buenos Aires
Country [28] 0 0
Argentina
State/province [28] 0 0
Córdova
Country [29] 0 0
Argentina
State/province [29] 0 0
San Juan
Country [30] 0 0
Canada
State/province [30] 0 0
British Columbia
Country [31] 0 0
Canada
State/province [31] 0 0
Manitoba
Country [32] 0 0
Canada
State/province [32] 0 0
Newfoundland and Labrador
Country [33] 0 0
Canada
State/province [33] 0 0
Nova Scotia
Country [34] 0 0
Canada
State/province [34] 0 0
Ontario
Country [35] 0 0
Canada
State/province [35] 0 0
Quebec
Country [36] 0 0
Colombia
State/province [36] 0 0
Bogotá
Country [37] 0 0
Costa Rica
State/province [37] 0 0
San José
Country [38] 0 0
Czech Republic
State/province [38] 0 0
Ceske Budejovice
Country [39] 0 0
Czech Republic
State/province [39] 0 0
Cheb
Country [40] 0 0
Czech Republic
State/province [40] 0 0
Olomouc
Country [41] 0 0
Czech Republic
State/province [41] 0 0
Praha 10
Country [42] 0 0
Czech Republic
State/province [42] 0 0
Praha 2
Country [43] 0 0
Czech Republic
State/province [43] 0 0
Praha 5
Country [44] 0 0
Ecuador
State/province [44] 0 0
Quito
Country [45] 0 0
Latvia
State/province [45] 0 0
Cesis
Country [46] 0 0
Latvia
State/province [46] 0 0
Daugavpils
Country [47] 0 0
Latvia
State/province [47] 0 0
Riga
Country [48] 0 0
Latvia
State/province [48] 0 0
Tukums
Country [49] 0 0
Mexico
State/province [49] 0 0
Baja California Norte
Country [50] 0 0
Mexico
State/province [50] 0 0
Hidalgo
Country [51] 0 0
Mexico
State/province [51] 0 0
Morelos
Country [52] 0 0
Mexico
State/province [52] 0 0
Nuevo León
Country [53] 0 0
Mexico
State/province [53] 0 0
Durango
Country [54] 0 0
Mexico
State/province [54] 0 0
Mexico, D.F.
Country [55] 0 0
New Zealand
State/province [55] 0 0
Auckland
Country [56] 0 0
New Zealand
State/province [56] 0 0
Christchurch
Country [57] 0 0
New Zealand
State/province [57] 0 0
Rotorua
Country [58] 0 0
New Zealand
State/province [58] 0 0
Tauranga
Country [59] 0 0
Peru
State/province [59] 0 0
Lima
Country [60] 0 0
Russian Federation
State/province [60] 0 0
Moscow
Country [61] 0 0
Russian Federation
State/province [61] 0 0
Perm
Country [62] 0 0
Russian Federation
State/province [62] 0 0
Samara
Country [63] 0 0
Russian Federation
State/province [63] 0 0
Tumen
Country [64] 0 0
Russian Federation
State/province [64] 0 0
Ufa
Country [65] 0 0
Russian Federation
State/province [65] 0 0
Yaroslavl

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This Phase 2 dose-ranging study will evaluate the efficacy, safety and tolerability of a
range of doses of GW677954 compared with placebo over sixteen weeks of treatment in subjects
with T2DM (Type 2 Diabetes Mellitus).
Trial website
https://clinicaltrials.gov/show/NCT00196989
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications